TGIF2 is a transcriptional repressor belonging to the TALE homeodomain superfamily that functions primarily as a negative regulator of gene expression 1. Mechanistically, TGIF2 represses transcription by binding directly to the DNA sequence 5'-CTGTCAA-3' and recruiting histone deacetylase proteins, particularly HDAC1, to target promoters 2. Phosphorylation of TGIF2 by EGFR/ERK signaling is critical for its transcriptional repression activity, particularly in suppressing E-cadherin expression 2. TGIF2 has significant disease relevance across multiple cancer types. In lung adenocarcinoma, phosphorylated TGIF2 promotes epithelial-mesenchymal transition (EMT) and metastasis through HDAC1-mediated E-cadherin repression 2. In pancreatic cancer, TGIF2 cooperates with Smad2 to co-regulate SOX2 promoter, driving EMT and cancer stem cell properties via EGFR/MAPK signaling 3. High TGIF2 expression in glioma correlates with poor prognosis, enhanced cell invasion and migration, and immune infiltration alterations 4. TGIF2 also promotes cervical cancer metastasis by negatively regulating FCMR 5. Clinically, TGIF2 represents a promising biomarker for cancer diagnosis and prognosis 4. Conversely, in pancreatic differentiation, microRNA-181c-5p targets TGIF2 to promote insulin-producing cell formation by modulating TGF-β-Smad2/3 signaling 6. In osteoarthritis, microRNA-34a induces synovial cell apoptosis through TGIF2 suppression 7.